BPC-157 and TB-500 Post-Surgery Recovery: What Is Known

What Is Known About BPC-157 After Surgery?

What is known about BPC-157 and TB-500 post surgery recovery comes from animals and cells, not patients. FDA's 2026 reviews list no human study of BPC-157 or TB-500 after surgery. In rodent (rat) studies, BPC-157 helped repair tendon, muscle and bowel joins. FDA found no human data on TB-500 at all.

Neither peptide is an FDA-approved drug. Both are banned in sport at all times. This page sets out what the studies show, what they do not, and FDA's legal record. It gives no start time and no dose, because no trial has tested either peptide after surgery. Our page on BPC-157 dosage in published studies lists the doses used in human and animal research.

Healing itself is well mapped. A review names four phases: stopping the bleeding, inflammation, new tissue growth and remodelling. In remodelling, the new tissue is laid out again and gets stronger. For a wound to heal well, all four must happen in the right order and time frame (Guo and DiPietro 2010). No study has tested where either peptide fits in that sequence in people.

Why the Two Are Paired

BPC-157 is a 15-amino-acid piece of a larger protein first found in human gastric juice. In cultured rodent (rat) tendon, BPC-157 sped up fibroblast outgrowth and migration. A fibroblast is the cell that rebuilds connective tissue. It also helped the cells survive stress, but did not change how fast they divided (Chang et al. 2011). In animal and lab studies, it also turned up signals for cell growth and new blood vessels (Vasireddi et al. 2025).

A review by its research group in Zagreb reports healing in rodent (rat) studies. The injuries were cut or detached tendons, and cut muscle, ligament and bone (Staresinic et al. 2022). The animals got it by injection into the belly, in drinking water, or on the injury.

TB-500 is not the same molecule as thymosin beta-4. FDA describes it as a piece of that protein, seven amino acids long (FDA 2026). The full protein holds actin, which cells use to move, in its loose single form. Thymosin beta-4 has a key role in skin and eye wound healing (Goldstein et al. 2005).

A review led by RegeneRx, a drug company, lists the full protein's effects. They include cell movement, new blood vessel growth and cell survival (Crockford et al. 2010). Those reviews cover thymosin beta-4, not TB-500. FDA's review came out before the rodent (rat) study below. It found no animal test of TB-500 itself for wound healing. In one lab test, it did not heal scratch wounds in dishes of fibroblasts.

So the idea is that BPC-157 helps blood supply and TB-500 helps cells move. The one controlled test of the pair we found is a rodent (rat) study of Achilles tendon repair (Biçer et al. 2026). That paper describes its TB-500 only as a synthetic peptide derived from thymosin beta-4, with no sequence. At four weeks, TB-500 alone made the repaired tendons significantly stronger than no treatment. BPC-157 alone did not reach significance. The pair did no better than either peptide alone. Each group had eight animals, and only four tendons per group were tested for strength. The authors call it an exploratory study with preliminary findings.

Is There a Proven Time to Start BPC-157 After Surgery?

No. No human study has tested when to start either peptide after an operation.

FDA's review lists the doses of BPC-157 given to people in small studies. They were given by enema (into the bowel), by injection into the knee or bladder, and by vein (FDA 2026). The studies were in bowel disease, bladder pain, knee pain and healthy volunteers. A registered trial of BPC-157 tablets posted no results. None was about healing after surgery. In the rodent (rat) tendon study above, the peptides went into the belly cavity for four weeks after the repair.

Timing around surgery also turns on bleeding, clotting and any drugs you take. Those are questions for your surgical team, who know the operation and your history.

Dosing After Surgery Has No Trial Behind It

No dose has been tested in people after surgery. A review for sports doctors found the right dose, how often and how long all unknown (Mayfield et al. 2026). FDA found no human data on how TB-500 moves through the body or leaves it. So this page gives no dose table. The table below shows what each study actually tested.

What the Rodent (Rat) Surgery Studies Gave

The rodent (rat) surgery studies below each state what they gave. These are animal doses in each study's own terms, not a guide for people. In a bowel join study, BPC-157 went into the belly cavity at 10 micrograms, 10 nanograms or 10 picograms per kg. The two higher doses improved healing (Vuksic et al. 2007). The Achilles-to-bone study used the same three doses into the belly, once a day (Krivic et al. 2006). The thigh muscle study gave 10 micrograms or 10 nanograms per kg a day by mouth (Matek et al. 2025).

What Are the Risks of BPC-157 Post Surgery?

Nobody knows the full list, because no one has studied either peptide for safety in people after surgery.

For BPC-157, FDA found too little safety data in people to judge its risks. Reports sent to FDA name injection site reactions, shortness of breath, and dark skin and gums. FDA says it is unclear whether BPC-157 caused them. The Vasireddi review found no human safety data. It flags risks from unregulated making and from contamination.

For TB-500, FDA found no human data by any route, so its risks in people are unknown. For both, FDA warns that compounded versions, made to order by a pharmacy, may trigger immune reactions (FDA safety page).

What is in the vial is another unknown. A 2022 study by a French drug-testing lab analysed three products sold online, two of them named TB500 and TB1000. It found that the contents of the TB500 and TB1000 products were not always consistent with their earlier descriptions. The authors call such products misbranded (wrongly labelled) and adulterated (altered by other contents). They say using them is dangerous, because nobody official controls how they are made (Delcourt et al. 2022).

Cancer is a real concern. In animal and lab studies, BPC-157 turned up signals for new blood vessel growth. A recent review lists abnormal blood vessel growth and cancer among the possible risks of unregulated peptides such as these two (Moiz et al. 2026). Raise any cancer history with your medical team.

If you are drug tested in sport, both are banned at all times. The World Anti-Doping Agency (WADA) has named BPC-157 on its banned list since 2022 (WADA 2022). It also bans thymosin beta-4 and anything made from it, such as TB-500 (WADA list).

Which Surgeries Have Been Studied

In people, none. The reviews cited here found no human study of either peptide after shoulder (rotator cuff), knee ligament (ACL), meniscus, Achilles or any other surgery.

In animals, most of the work is rodent (rat) studies of BPC-157. Its research group calls it an anti-ulcer peptide that stays stable in human gastric juice. Its reviews credit it with protecting the lining of the stomach and the whole gut (Sikiric et al. 2010). In rodent (rat) studies, it also improved healing at surgical joins between cut bowel ends (Sikiric et al. 2020). No human study has shown that.

Two rodent (rat) studies copied tendon and muscle surgery more closely. In one, the Achilles tendon was cut away from the heel bone. The authors say this injury does not heal on its own. BPC-157 shots into the belly improved tendon-to-bone healing. A corticosteroid drug, methylprednisolone, made healing worse, and BPC-157 given with it cut that harm (Krivic et al. 2006).

In the other, the thigh (quadriceps) muscle was cut away from the bone. BPC-157 was given by mouth. Untreated muscle did not heal. In treated rodents (rats), the muscle grew back onto the bone and walking fully recovered, at checks out to 90 days (Matek et al. 2025).

For tendon, muscle, ligament and bone, the rodent (rat) studies above are the evidence. Our best peptides for injury recovery guide compares the other peptides on the same terms.

Thymosin Beta-4 on Skin Wounds

The skin-wound data come from the full 43-amino-acid protein, thymosin beta-4, not from TB-500. In rodent (rat) wounds through the whole skin, thymosin beta-4 was put on the wound or injected into the belly cavity. Skin growth over the wound was 42% higher than with salt water at day 4. At day 7 it was as much as 61% higher (Malinda et al. 1999).

In people, one mid-stage (phase 2) trial put the full protein on leg ulcers caused by poor vein flow. The paper reports 73 people, randomly assigned to several gel strengths or to a placebo, a dummy gel with no peptide. They were treated at eight sites in Italy and Poland. The trial registry lists 72 people. The authors judged the safety acceptable and similar to placebo. They wrote that a 0.03% strength may have the potential to speed healing (Guarnera et al. 2010; NCT00832091). The registry names RegeneRx, a drug company, as the sponsor.

That 0.03% is the strength of a gel on a leg ulcer. It is not a dose of TB-500, and the trial did not test wounds from surgery.

Three Other Peptides

Three more peptides come up too: GHK-Cu, Thymosin Alpha-1, and CJC-1295 with Ipamorelin. The sports doctors' review found no human data backing GHK-Cu for muscle, bone or joint problems. In most studies in people, FDA's 2024 review found Thymosin Alpha-1 well tolerated (FDA review). It called the safety data insufficient only for its use with US flu vaccines. FDA's safety page covers compounded forms of it (FDA safety page). It says the safety information "is inadequate for the agency to sufficiently understand the extent of any safety issues".

Thymosin Alpha-1 and Ipamorelin have both been tried in people after surgery. Thymosin Alpha-1 is a separate peptide, not TB-500 or thymosin beta-4. One randomised trial took 400 people after bowel cancer surgery, all on chemo, and gave 200 of them the peptide as well. Those 200 had fewer infections and other problems after surgery (Niu et al. 2024). A smaller randomised trial took 57 people after liver cancer surgery. Of those, 18 got it along with TACE, a chemo treatment sent through the artery that feeds the liver. The cancer came back about as often within a year, but later (Cheng et al. 2004). Both trials looked at immune health and cancer, not tissue repair.

Ipamorelin was given by vein after bowel surgery. It did no better than a placebo, a dummy drip (FDA 2024). The CJC-1295 and ipamorelin guide and the GHK-Cu complete guide go further.

The US Legal Position

No US pharmacy may lawfully make either peptide today. Section 503A of US drug law sets three tests for any raw drug a pharmacy uses (21 USC 353a). It must have a USP monograph (an official quality standard), be part of an FDA-approved drug, or be on FDA's 503A bulks list.

FDA's reviews say neither has a USP monograph or is part of an approved drug. The bulks list holds six substances, and none is a peptide (21 CFR 216.23). A prescription does not change that.

The 2026 change people cite was a change to a list, not a new route. In April 2026, FDA took both off its 503A Category 2 list of risky substances. The requests to add them to the bulks list had been withdrawn (FDA list, 22 April 2026). FDA's safety page still names both as once in Category 2. For its July 2026 meeting, FDA proposed leaving both off the bulks list (FDA briefing). Its advisers only give advice, and FDA does not have to follow it (FDA meeting page).

Some sellers label peptide vials "research use only". In a 2024 warning letter, FDA said that label did not protect one seller (FDA letter). Its websites showed the peptides were meant for people. So FDA counted them as unapproved new drugs, meaning drugs sold without the FDA approval the law requires.

What Should You Take Away About BPC-157 Post Surgery?

BPC-157 and TB-500 post surgery recovery has no human trial behind it. The rodent (rat) and cell studies are real, but they do not give a start time, a dose or a length of use for people. FDA found no human data on TB-500 at all, and the one rodent (rat) test of the pair found no added benefit.

Recovery rests on the plan your surgical team sets: wound care, movement, loading and physio. Work with a qualified clinician who knows your case, and check the risks above before anything else.

Bibliography

• Guo S, DiPietro LA. Factors affecting wound healing. Journal of Dental Research, 2010.
• Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011.
• Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025.
• Staresinic M et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Staresinic et al., Biomedicines, 2022.
• Sikiric P et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Sikiric et al., Current Pharmaceutical Design, 2010.
• Sikiric P et al. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Sikiric et al., Current Pharmaceutical Design, 2020.
• Vuksic T et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surgery Today, 2007.
• Krivic A et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research, 2006.
• Matek D et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics, 2025.
• Malinda KM et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
• Guarnera G et al. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences, 2010. Trial registry entry NCT00832091.
• Delcourt V et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis, 2022.
• Goldstein AL et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005.
• Crockford D et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 2010.
• Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026.
• Mayfield CK et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026.
• Moiz A et al. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Missouri Medicine, 2026.
• Niu W et al. A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer. Niu et al., Biotechnology and Genetic Engineering Reviews, 2024.
• Cheng SQ et al. Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma. Chinese Journal of Oncology, 2004.
• U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA, content current as of 22 April 2026.
• U.S. Food and Drug Administration. FDA Briefing Documents for BPC-157 and TB-500 Related Bulk Drug Substances, PCAC meeting of 23 July 2026. BPC-157; TB-500.
• World Anti-Doping Agency. The 2026 Prohibited List. WADA, in effect 1 January 2026.

Disclaimer

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. BPC-157 and TB-500 are not approved by the FDA for any use. The evidence discussed here is mostly preclinical. Always work with a qualified clinician and your surgical team before making changes to your health protocol.